5.33
price down icon3.09%   -0.17
after-market Dopo l'orario di chiusura: 5.23 -0.10 -1.88%
loading
Precedente Chiudi:
$5.50
Aprire:
$5.49
Volume 24 ore:
69,382
Relative Volume:
0.46
Capitalizzazione di mercato:
$54.12M
Reddito:
$52.29M
Utile/perdita netta:
$-73.52M
Rapporto P/E:
-8.0758
EPS:
-0.66
Flusso di cassa netto:
$-100.45M
1 W Prestazione:
+6.18%
1M Prestazione:
+4.72%
6M Prestazione:
-36.32%
1 anno Prestazione:
-45.16%
Intervallo 1D:
Value
$5.16
$5.6761
Intervallo di 1 settimana:
Value
$4.95
$5.75
Portata 52W:
Value
$3.61
$13.44

Precision Biosciences Inc Stock (DTIL) Company Profile

Name
Nome
Precision Biosciences Inc
Name
Telefono
919-314-5512
Name
Indirizzo
302 EAST PETTIGREW STREET, DURHAM, NC
Name
Dipendente
108
Name
Cinguettio
@PrecisionBioSci
Name
Prossima data di guadagno
2024-11-04
Name
Ultimi documenti SEC
Name
DTIL's Discussions on Twitter

Confronta DTIL con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
DTIL
Precision Biosciences Inc
5.33 54.12M 52.29M -73.52M -100.45M -0.66
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
493.84 122.76B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
602.64 61.38B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
614.76 36.37B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
251.56 30.12B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
244.90 24.70B 3.81B -644.79M -669.77M -6.24

Precision Biosciences Inc Stock (DTIL) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-01-10 Aggiornamento BMO Capital Markets Market Perform → Outperform
2024-04-30 Iniziato Guggenheim Buy
2022-06-17 Iniziato BMO Capital Markets Outperform
2022-06-09 Downgrade William Blair Outperform → Mkt Perform
2020-07-27 Ripresa BTIG Research Buy
2020-04-03 Downgrade Goldman Buy → Neutral
2020-03-05 Iniziato Stifel Buy
2020-02-25 Iniziato William Blair Outperform
2019-08-09 Iniziato BTIG Research Buy
2019-07-16 Iniziato H.C. Wainwright Buy
2019-04-22 Iniziato Barclays Overweight
2019-04-22 Iniziato Goldman Buy
2019-04-22 Iniziato JP Morgan Overweight
2019-04-22 Iniziato Jefferies Buy
Mostra tutto

Precision Biosciences Inc Borsa (DTIL) Ultime notizie

pulisher
Apr 23, 2025

Trading (DTIL) With Integrated Risk Controls - news.stocktradersdaily.com

Apr 23, 2025
pulisher
Apr 16, 2025

DTIL Gets FDA's Fast Track Tag for Hepatitis B Gene Therapy, Stock Up - TradingView

Apr 16, 2025
pulisher
Apr 16, 2025

Precision BioSciences Receives U.S. FDA Fast Track Designation for PBGENE-HBV, a First-In-Class Gene Editing Therapy Designed to Eliminate the Root Cause of Chronic Hepatitis B | DTIL Stock News - GuruFocus

Apr 16, 2025
pulisher
Apr 15, 2025

FDA fast tracks Precision BioSciences’ hepatitis B treatment By Investing.com - Investing.com South Africa

Apr 15, 2025
pulisher
Apr 15, 2025

Precision BioSciences Receives U.S. FDA Fast Track Designation for PBGENE-HBV, a First-In-Class Gene Editing Therapy Designed to Eliminate the Root Cause of Chronic Hepatitis B - BioSpace

Apr 15, 2025
pulisher
Apr 15, 2025

Precision BioSciences stock rises following FDA Fast Track designation By Investing.com - Investing.com India

Apr 15, 2025
pulisher
Apr 15, 2025

Precision BioSciences Gets FDA Fast Track Label for PBGENE-HBV - marketscreener.com

Apr 15, 2025
pulisher
Apr 15, 2025

12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga

Apr 15, 2025
pulisher
Apr 15, 2025

FDA Fast Tracks Precision BioSciences' (DTIL) Hepatitis B Gene E - GuruFocus

Apr 15, 2025
pulisher
Apr 15, 2025

FDA fast tracks Precision BioSciences’ hepatitis B treatment - Investing.com Australia

Apr 15, 2025
pulisher
Apr 15, 2025

Precision BioSciences stock rises following FDA Fast Track designation - Investing.com Australia

Apr 15, 2025
pulisher
Apr 15, 2025

FDA Fast Tracks Precision BioSciences' (DTIL) Hepatitis B Gene Editing Program | DTIL Stock News - GuruFocus

Apr 15, 2025
pulisher
Apr 15, 2025

Precision Biosciences Receives U.S. FDA Fast Track Designation For Pbgene-Hbv - marketscreener.com

Apr 15, 2025
pulisher
Apr 15, 2025

Revolutionary Gene Editing Treatment for Hepatitis B Wins FDA Fast Track Status - Stock Titan

Apr 15, 2025
pulisher
Apr 04, 2025

SEC Form PRE 14A filed by Precision BioSciences Inc. - Quantisnow

Apr 04, 2025
pulisher
Apr 01, 2025

Precision BioSciences to Participate in the 24th Annual Needham Virtual Healthcare Conference - 01net

Apr 01, 2025
pulisher
Apr 01, 2025

Gene Editing Pioneer Precision BioSciences Reveals Latest ARCUS Platform Progress at Major Healthcare Conference - Stock Titan

Apr 01, 2025
pulisher
Mar 28, 2025

Precision Biosciences director Kevin Buehler buys $21,122 in stock - Investing.com Australia

Mar 28, 2025
pulisher
Mar 28, 2025

Precision Biosciences director Melinda Brown buys $8,735 in stock By Investing.com - Investing.com South Africa

Mar 28, 2025
pulisher
Mar 28, 2025

Precision Biosciences director Melinda Brown buys $8,735 in stock - Investing.com India

Mar 28, 2025
pulisher
Mar 28, 2025

Precision Biosciences director Kevin Buehler buys $21,122 in stock By Investing.com - Investing.com UK

Mar 28, 2025
pulisher
Mar 27, 2025

Precision BioSciences (DTIL) Reports Q4 Loss, Misses Revenue Estimates - MSN

Mar 27, 2025
pulisher
Mar 27, 2025

Precision Biosciences director Germano Geno J purchases $17,225 in stock By Investing.com - Investing.com Australia

Mar 27, 2025
pulisher
Mar 27, 2025

Precision Biosciences director Germano Geno J purchases $17,225 in stock - Investing.com India

Mar 27, 2025
pulisher
Mar 27, 2025

Precision BioSciences: Q4 Earnings Snapshot - Big Rapids Pioneer

Mar 27, 2025
pulisher
Mar 26, 2025

Precision BioSciences Reports Positive 2024 Financial Results - TipRanks

Mar 26, 2025
pulisher
Mar 26, 2025

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business Update - CRISPR Medicine News

Mar 26, 2025
pulisher
Mar 26, 2025

Precision BioSciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 26, 2025
pulisher
Mar 26, 2025

PRECISION BIOSCIENCES Earnings Results: $DTIL Reports Quarterly Earnings - Nasdaq

Mar 26, 2025
pulisher
Mar 26, 2025

Precision Biosciences Reports Fourth Quarter And FY 2024 Results - MarketScreener

Mar 26, 2025
pulisher
Mar 26, 2025

Precision BioSciences Inc Q4 Sales Decline - Nasdaq

Mar 26, 2025
pulisher
Mar 25, 2025

Precision Biosciences CEO sells $5,359 in stock By Investing.com - Investing.com Australia

Mar 25, 2025
pulisher
Mar 25, 2025

Precision Biosciences CEO sells $5,359 in stock - Investing.com India

Mar 25, 2025
pulisher
Mar 25, 2025

Character Biosciences Raises $93 Million Series B to Advance Precision Medicine for Progressive Eye Diseases - Business Wire

Mar 25, 2025
pulisher
Mar 23, 2025

PRECISION BIOSCIENCES Earnings Preview: Recent $DTIL Insider Trading, Hedge Fund Activity, and More - Nasdaq

Mar 23, 2025
pulisher
Mar 23, 2025

Gene Editing Tools Market Growth Demand, Segment Analysis - openPR.com

Mar 23, 2025
pulisher
Mar 21, 2025

Precision BioSciences to Report Fourth Quarter and Fiscal Year 2024 Results on March 26, 2025 - BioSpace

Mar 21, 2025

Precision Biosciences Inc Azioni (DTIL) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$20.59
price up icon 0.24%
$69.69
price up icon 1.06%
$32.20
price up icon 0.53%
$23.46
price down icon 36.06%
$102.02
price down icon 15.36%
biotechnology ONC
$244.90
price down icon 4.40%
Capitalizzazione:     |  Volume (24 ore):